

December 21, 2010

Press Release

[Mitsubishi Tanabe Pharma Corporation](#)

Out-Licensing of Bepotastine Besilate for Ophthalmic Use to a South Korea

Osaka, Japan, December 21, 2010---Mitsubishi Tanabe Pharma Corporation (President & CEO: Michihiro Tsuchiya) today announced that the Company has concluded an agreement with Dong-A Pharmaceutical Co., Ltd. (head office: Seoul, South Korea; President & CEO: Won-Bae Kim) under which Mitsubishi Tanabe shall grant an exclusive Korean rights to develop, manufacture, and market bepotastine besilate, the active ingredient of TALION[®], for ophthalmic use.

Bepotastine besilate was co-developed by Mitsushi Tanabe Pharma and Ube Industries, Ltd. (head office: Ube, Yamaguchi, Japan; President & Representative Director: Michio Takeshita) who discovered, and then it has been marketed in Japan by Mitsubishi Tanabe Pharma for treatment of allergic disorders under the brand name TALION[®] since 2000. In South Korea, Dong-A Pharmaceutical has marketed it as TALION[®] Tablets since 2004, under the licensing agreement with the Company, and now keeps the top share in Korean anti-histamine market.

Dong-A Pharmaceutical plans to make its efforts to develop an eyedrop formulation of TALION[®], and aims to launch it in 2012. With this new lineup, Dong-A Pharmaceutical will bolster its franchise of both TALION[®] and its ophthalmologic field in South Korea. Mitsubishi Tanabe Pharma, through this strategic alliance, continues to maximize the product value of TALION[®].

Contact for further information:
Corporate Communications Department
Phone: +81 6-6205-5211